Targeted therapy for thyroid cancer: An updated review of investigational agents

Current Opinion in Investigational Drugs

Volumn 11, Issue 6, 2010, Pages 661-668

  Deshpande, Hari A ^a   Gettinger, Scott N ^a   Sosa, Julie A ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplastic thyroid cancer; Angiogenesis inhibitor; BRAF; Differentiated thyroid cancer; Medullary thyroid cancer; RET; Targeted therapy; Tyrosine kinase inhibitor; VEGFR

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AXITINIB; AZACITIDINE; B RAF KINASE; BORTEZOMIB; CARBOPLATIN; CS 7017; EVEROLIMUS; FOSBRETABULIN; GEFITINIB; INOLITAZONE; LIVER ENZYME; MOTESANIB; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLX 4032; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VORINOSTAT; XL 184;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CARCINOGENESIS; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KERATOACANTHOMA; LEUKEMIA; MYELODYSPLASTIC SYNDROME; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR TARGETED THERAPY; THYROID NEOPLASMS;

EID: 77952896418     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin (2009) 59(4):225-249.
2. Colonna M, Guizard AV, Schvartz C, Velten M, Raverdy N, Molinie F, Delafosse P, Franc B, Grosclaude P: A time trend analysis of papillary and follicular cancers as a function of tumour size: A study of data from six cancer registries in France (1983-2000). Eur J Can (2007) 43(5):891-900.
3. Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 295(18):2164-2167.
4. Carling T, Udelsman R: Cancer of the endocrine system: Section 2 thyroid tumors. In: Cancer Principles and Practice. De Vita V, Hellman S, Rosenberg S (Eds), Lippincott Williams and Wilkins, Philadelphia, PA, USA (2005):1503-1521.
5. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M: Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 91(8):2892-2899.
6. Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, Shong YK: Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J (2009) 56(1): 105-112.
7. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H, Zhu C: A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun (2007) 28(4): 251-255.
8. Ekman ET, Lundell G, Tennvall J, Wallin G: Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am (1990) 23(5):523-527.
9. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med (1971) 285(21):1182-1186.
10. Sivakumar B, Harry LE, Paleolog EM: Modulating angiogenesis: More vs less. JAMA (2004) 292(8):972-977.
11. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikirov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 63(7):1454-1457.
12. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol (2008) 26(29):4708-4713.
13. Gupta V, Puttaswamy K, Lassoued W, Redlinger K, Ransone K, Gold K, Lee W, LiVolsi V, Fraker D, Mandel S, Brose M: Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. J Clin Oncol (2007) 25(18 Suppl):Abs 6019.
14. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 26(29):4714-4719.
15. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, Aractingi S, Grange JD, Poirier-Colame V, Malka D, Soria JC et al: Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 27(23):e59-e61.
16. Kwon EJ, Kish LS, Jaworsky C: The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol (2009) 61(3):522-527.
17. National Comprehensive Cancer Network: National Comprehensive Cancer Network, Fort Washington, PA, USA (2010). www.nccn.org
18. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, Villaflor VM, Seiwert TY, Nichols K, Vokes EE: Phase II study of sunitinib in refractory thyroid cancer. J Clin Oncol (2008) 26(Suppl):Abs 6025.
19. Ravaud A, de la Fouchardière C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P, Bournaud C, Delord J, Weryha G, Catargi B: Sunitinib in patients with refractory advanced thyroid cancer: The THYSU phase II trial. J Clin Oncol (2008) 26(Suppl):Abs 6058.
20. Sherman SI, Wirth LJ, Droz JP, Hoffman M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE et al: Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 359(1):31-42.
21. Puzanov I, Nathanson KL, Chapman PB, Xu X, Sosman JA, McArthur GA, Ribas A, Kim KB, Grippo JF, Flaherty KT: PLX4032 A highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. J Clin Oncol (2009) 27(Suppl 15):Abs 9021.
22. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P: Phase I study of PLX4032: Proof of concept for V600EBRAF mutation as a therapeutic target in human cancer. J Clin Oncol (2009) 27(Suppl 15):Abs 9000.
23. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G: Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab (2010) 95(1):450-455.
24. AstraZeneca plc: AstraZeneca Announces US Label Change for IRESSA (gefitinib) and New Distribution Program. Press Release (2005): June 17.
25. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC et al: Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res (2004) 10(24):8594-8602.
26. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR et al: A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid (2008) 18(3):317-323.
27. Roman S, Lin R, Sosa JA: Prognosis of medullary thyroid carcinoma: Demographic, clinical and pathological predictors of survival in 1252 cases. Cancer (2006) 107(9):2134-2142.
28. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 27(23):3794-3801.
29. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ et al: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA (1996) 276(19):1575-1579.
30. Eng C: RET proto-oncogene in the development of human cancer. J Clin Oncol (1999) 17(1):380-393.
31. Messina M, Robinson BG: Technology insight: Gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab (2007) 3(3):290-301.
32. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res (2002) 62(16):4645-4655.
33. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 62(24):7284-7290.
34. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ: Vandetanib (ZD6474): An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs (2007) 16(2):239-249.
35. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 28(5):767-772.
36. Haddad RI, Krebs AD, Vasselli J, Paz-Ares LG, Robinson B: A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2008) 26(Suppl):Abs 6024.
37. Kurzrock R, Sherman S, Hong D, Ng C, Frye J, Janisch L, Ratain MJ, Salgia R: A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies including a subgroup of pts with medullary thyroid cancer (MTC). Proc 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland (2008) 119:Abs 379.
38. Chan P, Yau T, Epstein R, Lam K, Liang R, Lo C: Treatment outcomes in anaplastic thyroid carcinoma from 1966-2006. Failure of overall survival enhancement despite four decades of progress in surgery, radiotherapy and chemoradiation. J Clin Oncol (2007) 25(Suppl 18):Abs 16537.
39. Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, Fernandes JK: Anaplastic thyroid carcinoma: An overview. Curr Oncol Rep (2007) 9(2):152-158.
40. Brignardello E, Gallo M, Baldi I, Palestini N, Piovesan A, Grossi E, Ciccone G, Boccuzzi G: Anaplastic thyroid carcinoma: Clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol (2007) 156(4):425-430.
41. Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM et al: A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid (2009) 19(3):233-240.
42. OXiGENE Inc: OXiGENE announces restructuring to focus resources on key programs and provides business update. Press Release (2010): February 11.
43. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F et al: Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. J Cell Physiol (2007) 212(2):330-344.
44. Esteller M: Epigenetics in cancer. N Eng J Med (2008) 358(11): 1148-1159.
45. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L, Fusco A: Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasomedependent inhibition of TRAIL degradation. Oncogene (2010) 29(1):105-116.
46. Shimazaki N, Togashi N, Hanai M, Isoyama T, Wada K, Fujita T, Fujiwara K, Kurakata S: Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor ã agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer (2008) 44(12):1734-1743.